In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Beyondspring Inc (NASDAQ: BYSI), with a price target of $60. The company’s shares closed yesterday at $26.48.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.9% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Beyondspring Inc is Moderate Buy and the average price target is $56, representing an 111.5% upside.
In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $52 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $48.49 and a one-year low of $19.55. Currently, Beyondspring Inc has an average volume of 15.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
